Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applovin Corporation (APP) vs Mesoblast Limited (MESO) Price & Performance

Applovin CorporationTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Applovin Corporation vs Mesoblast Limited — how do they compare? Applovin Corporation trades at $319.21 (market cap $113.45B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Applovin Corporation is far larger — about 52.5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.

APPMESO
Market Cap
$113.45B$2.16B
Sector
TechnologyTechnology
52-Week High
$733.60$20.96
52-Week Low
$335.67$12.88
Enterprise Value
$113.91B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applovin Corporation

AppLovin (APP) trades at $346.80, down 3.32% amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure after Q2 revenue missed expectations, though it maintains exceptional profitability with 64.58% net margins and 53% YoY revenue growth. Analyst consensus remains bullish with an $569.60 price target, but technical indicators show 18 sell signals versus 2 buys.

The stock presents a growth-at-a-reasonable-price opportunity post-selloff, trading at 26x P/E with 80% analyst buy ratings. Key risks include execution volatility in AI-driven ad pricing and high valuation multiples. Upside depends on Q3 results meeting elevated guidance of 47% growth.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applovin Corporation

AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.

Read more on APP

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO